PF-5190457: Clinical Trials

5 trials of PF-5190457, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Terminated 1
Phase 21Terminated 1

Follow this drug Literature Review of PF-5190457 trials Research Report on PF-5190457

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II
PF-05190457, Placebo - Alcoholism
Phase 2TerminatedNational Institute on Alcohol Abuse and Alcoholism (NIAAA)422016-06-152022-03-16
A Novel Compound for Alcoholism Treatment
PF-05190457 - Alcoholism, Alcohol-Related Disorders
Phase 1CompletedNational Institute on Alcohol Abuse and Alcoholism (NIAAA)142014-01-032019-12-16
A Study Of Three PF-05190457 Formulations In Healthy Volunteers
PF-05190457 - Diabetes Mellitus, Type 2
Phase 1CompletedPfizer162011-09-012012-02-01
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
PF-05190457 or Placebo - Diabetes Mellitus, Type 2
Phase 1TerminatedPfizer352011-07-012012-05-23
Single Dose Escalation Study of PF-05190457 in Healthy Volunteers
PF-05190457, Placebo - Diabetes Mellitus, Type II
Phase 1CompletedPfizer262010-12-012011-07-06

Conditions studied

Diabetes Mellitus, Type 2 (3)  ·  Alcohol Drinking (2)  ·  Alcoholism (2)  ·  Alcohol-Related Disorders (1)

Sponsors

Pfizer (3)  ·  National Institute on Alcohol Abuse and Alcoholism (NIAAA) (2)

Countries

United States (3)  ·  Belgium (1)  ·  Singapore (1)

Top investigators

Lorenzo Leggio, M.D. (1)  ·  Lorenzo Leggio, M.D., PhD (1)

Results publications

PMID 33155163, PMID 27621150, PMID 31557492, PMID 39704175, PMID 41474196